Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Downsview Capital
investment firm
About
Downsview Capital, Inc. is a Illinois-based investment advisor that manages the private equity funds including Cranshire Capital, L.P.
- Deerfield,Illinois,United States
Highlights
Details
- Operating Status
- Active
- Investor Type
- PE
Downsview Capital, Inc. is a Illinois-based investment advisor that manages the private equity funds including Cranshire Capital, L.P.
Investments
Number of Investments
Number of Lead Investments
6
0
Downsview Capital has made 6 investments. Their most recent investment was on
Sep 24, 2010, when Cascadian Therapeutics raised $14.90M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Sep 24, 2010
Cascadian Therapeutics
|
Post-IPO Equity | $14.90M | Biotechnology | — |
|
Jul 2, 2010
Soligenix
|
Series Unknown | $5.90M | Biopharma | — |
|
Feb 24, 2010
SinoHub
|
Series Unknown | $4.61M | Electronics | — |
|
Aug 4, 2009
Agenus
|
Post-IPO Equity | $10M | Biotechnology | — |
|
Dec 13, 2005
EUSA Pharma
|
Series Unknown | $12.53M | Biotechnology | — |
Exits
Downsview Capital has had 5 exits. Downsview Capital most notable exits include EUSA Pharma , Soligenix
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Dec 2, 2021 | EUSA Pharma | M&A | Biotechnology | Detail |
| Dec 13, 2016 | Soligenix | IPO | Biopharma | Detail |
| Sep 24, 2008 | Pharmacopeia | M&A | Biopharma | Detail |
| Feb 11, 2000 | Agenus | IPO | Biotechnology | Detail |
| Nov 29, 1991 | Cascadian Therapeutics | M&A | Biotechnology | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
